
-
Chimerix Inc. NasdaqGM:CMRX Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases in the United States. Its product pipeline comprising dordaviprone (ONC201), which is in phase 3 clinical-stage development for H3 K27M-mutant diffuse glioma, as well as in phase 2 Investigator Initiated Clinical Trials for multiple oncology studies; and ONC206, a second generation imipridone ClpP agonist and DRD2 antagonist which is in phase 1 clinical trial to treat central nervous systems and other solid tumors. The company also develops ONC212, an imipridone, investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP, which is in preclinical trial; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of novel coronaviruses. In addition, it offers TEMBEXA, a lipid conjugate which acts via inhibition of viral DNA synthesis that is a medical countermeasure for smallpox. The company has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina. As of April 17, 2025, Chimerix, Inc. operates as a subsidiary of Jazz Pharmaceuticals plc.
Location: 2505 Meridian Parkway, Durham, NC, 27713, United States | Website: https://www.chimerix.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
670.6M
Cash
131.6M
Avg Qtr Burn
-18.74M
Short % of Float
4.21%
Insider Ownership
1.73%
Institutional Own.
56.44%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TEMBEXA (brincidofovir) Details Smallpox | Approved Quarterly sales | |
Dordaviprone (ONC201) Details Pediatric recurrent H3K27M glioma | PDUFA Approval decision | |
ONC206 Details Brain tumor, Solid tumor/s, Glioblastoma | Phase 1 Data readout | |
Dociparstat sodium (DSTAT) Details Infectious disease, COVID-19 | Failed Discontinued | |
Dociparstat sodium (DSTAT) Details Cancer, Acute myeloid leukemia | Failed Discontinued |